Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats
Tóm tắt
Tetrathiomolybdate (TM), a drug developed for Wilson's disease, produces an anti-angiogenic and anti-inflammatory effect by reducing systemic copper levels. TM therapy has proved effective in inhibiting the growth of tumors in animal tumor models and in cancer patients. We have hypothesized that TM may be used for the therapy of rheumatoid arthritis and have examined the efficacy of TM on adjuvant-induced arthritis in the rat, which is a model of acute inflammatory arthritis and inflammatory cachexia. TM delayed the onset of and suppressed the severity of clinical arthritis on both paw volume and the arthritis score. Histological examination demonstrated that TM significantly reduces the synovial hyperplasia and inflammatory cell invasion in joint tissues. Interestingly, TM can inhibit the expression of vascular endothelial growth factor in serum synovial tissues, especially in endothelial cells and macrophages. Moreover, the extent of pannus formation, which leads to bone destruction, is correlated with the content of vascular endothelial growth factor in the serum. There was no mortality in TM-treated rat abnormalities. TM also suppressed inflammatory cachexia. We suggest that copper deficiency induced by TM is a potent approach both to inhibit the progression of rheumatoid arthritis with minimal adverse effects and to improve the well-being of rheumatoid arthritis patients.
Tài liệu tham khảo
Feldmann M, Brennan FM, Maini RN: Rheumatoid arthritis. Cell. 1996, 85: 307-310. 10.1016/S0092-8674(00)81109-5.
Koch AE: Angiogenesis: implication of rheumatoid arthritis. Arthritis Rheum. 1998, 41: 951-962. 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D.
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995, 1: 27-31. 10.1038/nm0195-27.
Ferrara N, Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999, 5: 1359-1364. 10.1038/70928.
Firestein GS: Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors?. Arthritis Rheum. 1996, 39: 1781-1790.
Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N: Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol. 1994, 152: 4149-4156.
Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, Paleolog EM: Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 2001, 44: 2055-2064. 10.1002/1529-0131(200109)44:9<2055::AID-ART355>3.0.CO;2-2.
Scola MP, Imagawa T, Boivin GP, Giannini EH, Glass DN, Hirsch R, Grom AA: Expression of angiogenic factors in juvenile rheumatoid arthritis: correlation with revascularization of human synovium engrafted into SCID mice. Arthritis Rheum. 2001, 44: 794-801. 10.1002/1529-0131(200104)44:4<794::AID-ANR135>3.0.CO;2-7.
Weber AJ, De Bandt M, Gaudry M: Immunohistochemical analysis of vascular endothelial growth factor expression in severe and destructive rheumatoid arthritis. J Rheumatol. 2000, 27: 2284-2286.
Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H: Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and endothelial growth factor by synovial fibroblasts. Arthritis Rheum. 2002, 46: 2587-2597. 10.1002/art.10520.
Henriksen K, Karsdal M, Delaisse JM, Engsig MT: RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem. 2003, 278: 48745-48753. 10.1074/jbc.M309193200.
Matsumoto Y, Tanaka K, Hirata G, Hanada M, Matsuda S, Shuto T, Iwamoto Y: Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol. 2002, 168: 5824-5831.
Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M, Maini RN: Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol. 1992, 31: 801-809.
Sano H, Forough R, Maier JA, Case JP, Jackson A, Engleka K, Maciag T, Wilder RL: Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol. 1990, 110: 1417-1426. 10.1083/jcb.110.4.1417.
Rall LC, Roubenoff R: Rheumatoid cachexia: metabolic abnormalities, mechanism and interventions. Rheumatology (Oxford). 2004, 43: 1219-1223. 10.1093/rheumatology/keh321.
Joosten LA, Helsen MM, van de Loo FA, van den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 1996, 39: 797-809.
Thomas JW, Thieu TH, Byrd VM, Miller GG: Acidic fibroblast growth factor in synovial cells. Arthritis Rheum. 2000, 43: 2152-2159. 10.1002/1529-0131(200010)43:10<2152::AID-ANR2>3.3.CO;2-I.
Paget J: Nervous mimicry of organic diseases. Lancet. 1873, 102: 727-729. 10.1016/S0140-6736(02)69188-3.
Roubenoff R, Kehayias JJ: The meaning and measurement of lean body mass. Nutr Rev. 1991, 49: 163-175.
Schilsky ML: Diagnosis and treatment of Wilson's disease. Pediatr Transplant. 2002, 6: 15-19. 10.1034/j.1399-3046.2002.1r069.x.
Landriscina M, Bagala C, Mandinova A, Soldi R, Micucci I, Bellum S, Prudovsky I, Maciag T: Copper induces the assembly of a multiprotein aggregate implicated in the release of fibroblast growth factor 1 in response to stress. J Biol Chem. 2001, 276: 25549-25557. 10.1074/jbc.M102925200.
Mandinov L, Mandinova A, Kyurkchiev S, Kyurkchiev D, Kehayov I, Kolev V, Soldi R, Bagala C, de Muinck ED, Lindner V, et al: Copper chelation represses the vascular response to injury. Proc Natl Acad Sci USA. 2003, 100: 6700-6705. 10.1073/pnas.1231994100.
Prudovsky I, Mandinova A, Soldi R, Bagala C, Graziani I, Landriscina M, Tarantini F, Duarte M, Bellum S, Doherty H, Maciag T: The non-classical export routes: FGF1 and IL-1alpha point the way. J Cell Sci. 2003, 116: 4871-4881. 10.1242/jcs.00872.
Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA: A treatment of Wilson's disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 1996, 53: 1017-1025.
Brewer GJ, Merajver SD: Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper – a review. Integr Cancer Ther. 2002, 1: 327-337. 10.1177/1534735402238185.
Khan MK, Miller MW, Taylor J, Gill NK, Dick RD, Van Golen K, Brewer GJ, Merajver SD: Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia. 2002, 4: 164-170. 10.1038/sj.neo.7900218.
Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, et al: Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 2002, 62: 4854-4859.
Sen CK, Khanna S, Venojarvi M, Trikha P, Ellison EC, Hunt TK, Roy S: Copper-induced vascular endothelial growth factor expression and wound healing. Am J Physiol Heart Circ Physiol. 2002, 282: H1821-H1827.
Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD: Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res. 2003, 9: 1666-1672.
Percival SS: Copper and immunity. Am J Clin Nutr. 1998, 67: 1064-1068.
Brewer GJ, Ullenbruch MR, Dick R, Olivarez L, Phan SH: Tetrathiomolybdate therapy protects against bleomycin-pulmonary fibrosis in mice. J Lab Clin Med. 2003, 141: 210-216. 10.1067/mlc.2003.20.
Marikovsky M, Ziv V, Nevo N, Harris-Cerruti C, Mahler O: Cu/Zn superoxide plays important role in immune response. J Immunol. 2003, 170: 2993-3001.
Honkanen V, Konttinen YT, Sorsa T, Hukkanen M, Kemppinen P, Santavirta S, Saari H, Westermarck T: Serum zinc, copper and selenium in rheumatoid arthritis. J Trace Elem Electrolytes Health Dis. 1991, 5: 261-263.
Zoli A, Altomonte L, Caricchio R, Galossi A, Mirone L, Ruffini MP, Magaro M: Serum zinc and copper in active rheumatoid arthritis: correlation with interleukin 1 beta and tumour necrosis factor alpha. Clin Rheumatol. 1998, 17: 378-382. 10.1007/BF01450895.
Harada S, Sugiyama E, Taki H, Shinoda K, Fujita T, Maruyama M, Kobayashi M: D-penicillamine cooperates with copper sulfate to enhance the surface expression of functional Fas antigen in rheumatoid synovial fibroblasts via the generation of hydrogen peroxide. Clin Exp Rheumatol. 2002, 20: 469-476.
Brewer GJ: Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J Cell Mol Med. 2003, 7: 11-20.
Sano H, Hla T, Maier JA, Crofford LJ, Case JP, Maciag T, Wilder RL: In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant streptococcal cell wall arthritis. J Clin Invest. 1992, 89: 97-108.
Kawahito Y, Cannon GW, Gulko PS, Remmers EF, Longman RE, Reese VR, Wang J, Griffiths MM, Wilder RL: Localization of quantitative trait loci regulating adjuvant-induced arthritis in rats: evidence for genetic factors common to multiple autoimmune diseases. J Immunol. 1998, 161: 4411-4419.
Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, Kohno M, Yamada R, Hla T, Sano H: 15-deoxy-delta(12,14)-PGJ2 induces synoviovyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest. 2000, 106: 189-197.
Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, et al: Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, and antiangiogenic agent: phase I study. Clin Cancer Res. 2000, 6: 1-10.
Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K, Miyasaka N: Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med. 1999, 5: 760-767. 10.1038/10480.
Milanino R, Frigo A, Bambara LM, Marrella M, Moretti U, Pasqualicchio M, Biasi D, Gasperini R, Mainenti L, Velo GP: Copper and zinc status in rheumatoid arthritis: studies of plasma, erythrocytes and urine, and their relationship to disease activity markers and pharmacological treatment. Clin Exp Rheumatol. 1993, 11: 271-281.
Honkanen VE, Lamberg-Allardt CH, Vesterinen MK, Lehto JH, Westermarck TW, Metsa-Ketela TK, Mussalo-Rauhamaa MH, Konttinen YT: Plasma zinc and copper concentrations in rheumatoid arthritis: influence of dietary factors and disease activity. Am J Clin Nutr. 1991, 54: 1082-1086.
Milanino R, Moretti U, Concari E, Marrella M, Velo GP: Copper and zinc status in rats and acute inflammation: focus on the inflamed area. Agents Actions. 1988, 24: 356-364.
Mandinova A, Soldi R, Graziani I, Bagala C, Bellum S, Landriscina M, Tarantini F, Prudovsky I, Maciag T: S100A13 mediates the copper-dependent stress-induced release of IL-1alpha from both human U937 and murine NIH 3T3 cells. J Cell Sci. 2003, 116: 2687-2696. 10.1242/jcs.00471.
De Bandt M, Ben Mahdi MH, Ollivier V, Grossin M, Dupuis M, Gaudry M, Bohlen P, Lipson KE, Rice A, Wu Y, et al: Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol. 2003, 171: 4853-4859.
Taylor PC: Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology (Oxford). 2005, 44: 721-728. 10.1093/rheumatology/keh524.
Roubenoff R, Freeman LM, Smith DE, Abad LW, Dinarello CA, Kehayias JJ: Adjuvant arthritis as a model of inflammatory cachexia. Arthritis Rheum. 1997, 40: 534-539.
Ahima RS, Flier JS: Leptin. Annu Rev Physiol. 2000, 62: 413-437. 10.1146/annurev.physiol.62.1.413.
Fantuzzi G, Faggioni R: Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000, 68: 437-446.
Zarkesh-Esfahani H, Pockley G, Metcalfe RA, Bidlingmaier M, Wu Z, Ajami A, Weetman AP, Strasburger CJ, Ross RJ: High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol. 2001, 167: 4593-4599.